It is conceivable to achieve high benefit-to-harm ratio for treating MI and HF by liver-specific delivery of MR antagonists, monoclonal antibodies against MR, or even MR-editing CRISPR-Cas9 system using strategies such as nanotechnology and hepatocyte-specific promoters (54, 55). The gene discussed is NR3C2; the disease is hydrops fetalis.